These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 28807656)
1. Opportunities for model-based precision dosing in the treatment of sickle cell anemia. Dong M; Mizuno T; Vinks AA Blood Cells Mol Dis; 2017 Sep; 67():143-147. PubMed ID: 28807656 [TBL] [Abstract][Full Text] [Related]
2. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. Dong M; McGann PT; Mizuno T; Ware RE; Vinks AA Br J Clin Pharmacol; 2016 Apr; 81(4):742-52. PubMed ID: 26615061 [TBL] [Abstract][Full Text] [Related]
3. Rationale, Development, and Validation of HdxSim, a Clinical Decision Support Tool for Model-Informed Precision Dosing of Hydroxyurea for Children with Sickle Cell Anemia. Power-Hays A; Dong M; Punt N; Mizuno T; Smart LR; Vinks AA; Ware RE Clin Pharmacol Ther; 2024 Sep; 116(3):670-677. PubMed ID: 38018175 [TBL] [Abstract][Full Text] [Related]
4. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. McGann PT; Niss O; Dong M; Marahatta A; Howard TA; Mizuno T; Lane A; Kalfa TA; Malik P; Quinn CT; Ware RE; Vinks AA Am J Hematol; 2019 Aug; 94(8):871-879. PubMed ID: 31106898 [TBL] [Abstract][Full Text] [Related]
5. Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. Quinn CT; Niss O; Dong M; Pfeiffer A; Korpik J; Reynaud M; Bonar H; Kalfa TA; Smart LR; Malik P; Ware RE; Vinks AA; McGann PT Br J Haematol; 2021 Aug; 194(3):617-625. PubMed ID: 34227124 [TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea: Analytical techniques and quantitative analysis. Marahatta A; Ware RE Blood Cells Mol Dis; 2017 Sep; 67():135-142. PubMed ID: 28847416 [TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea therapy for sickle cell anemia. McGann PT; Ware RE Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626 [TBL] [Abstract][Full Text] [Related]
8. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146 [TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial. Aygun B; Lane A; Smart LR; Santos B; Tshilolo L; Williams TN; Olupot-Olupot P; Stuber SE; Tomlinson G; Latham T; Ware RE; Lancet Haematol; 2024 Jun; 11(6):e425-e435. PubMed ID: 38701812 [TBL] [Abstract][Full Text] [Related]
10. Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine. Dong M; McGann PT Clin Pharmacol Ther; 2021 Jan; 109(1):73-81. PubMed ID: 32869281 [TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813 [TBL] [Abstract][Full Text] [Related]
12. Computer Algorithm-Based Hydroxyurea Dosing Facilitates Titration to Maximum Tolerated Dose in Sickle Cell Anemia. Oldham M; Conrey A; Pittman C; Fisher C; Hargrett S; West K; Jackson M; Martin S; Hsieh MM; Jeffries N; Kaplarevic M; Johnson D; Olkhanud P; Fitzhugh CD J Clin Pharmacol; 2021 Jan; 61(1):41-51. PubMed ID: 32673439 [TBL] [Abstract][Full Text] [Related]
13. Hydroyxurea improves cerebral oxygen saturation in children with sickle cell anemia. Karkoska K; Quinn CT; Niss O; Pfeiffer A; Dong M; Vinks AA; McGann PT Am J Hematol; 2021 May; 96(5):538-544. PubMed ID: 33534136 [TBL] [Abstract][Full Text] [Related]
14. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679 [TBL] [Abstract][Full Text] [Related]
15. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease. Brandow AM; Panepinto JA Am J Hematol; 2011 Sep; 86(9):804-6. PubMed ID: 21815183 [TBL] [Abstract][Full Text] [Related]
16. Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience. Karkoska K; Todd K; Niss O; Clapp K; Fenchel L; Kalfa TA; Malik P; Quinn CT; Ware RE; McGann PT Pediatr Blood Cancer; 2021 Jun; 68(6):e29008. PubMed ID: 33742510 [TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia. Meier ER; Creary SE; Heeney MM; Dong M; Appiah-Kubi AO; Nelson SC; Niss O; Piccone C; Quarmyne MO; Quinn CT; Saving KL; Scott JP; Talati R; Latham TS; Pfeiffer A; Shook LM; Vinks AA; Lane A; McGann PT Trials; 2020 Nov; 21(1):983. PubMed ID: 33246482 [TBL] [Abstract][Full Text] [Related]
18. Hydroxycarbamide: clinical aspects. Ware RE C R Biol; 2013 Mar; 336(3):177-82. PubMed ID: 23643402 [TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. Aygun B; Mortier NA; Smeltzer MP; Shulkin BL; Hankins JS; Ware RE Am J Hematol; 2013 Feb; 88(2):116-9. PubMed ID: 23255310 [TBL] [Abstract][Full Text] [Related]
20. Increasing hydroxyurea use in children with sickle cell disease at Kamuzu Central Hospital, Malawi. Mvalo T; Topazian H; Kamthunzi P; Chen J; Kambalame I; Mafunga P; Mumba N; Chiume-Chiphaliwali M; Paseli K; Key N; Gopal S; Hoffman I; Ataga K; Westmoreland K Blood Adv; 2018 Nov; 2(Suppl 1):30-32. PubMed ID: 30504195 [No Abstract] [Full Text] [Related] [Next] [New Search]